Phase 1 Obesity Trial, Recruiting NCT06934408 Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Condition: Obesity
Back to Obesity

Phase 1 Obesity Trial, Recruiting

NCT06934408
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to voluntarily sign a consent form, understand what the study involves, and agree to follow the study procedures throughout.
  • Men or women between 18 and 55 years old (inclusive).
  • People who are generally in good health, as assessed by the study doctor based on medical history, physical check-up, blood tests, and heart tracing (ECG) results.
  • People whose body weight has not changed by more than 5 kg in the 3 months before joining the trial.
  • Women who could become pregnant must agree to use highly effective contraception and avoid donating eggs from the time of signing the consent form until 6 months after the last dose, must have a negative blood pregnancy test before starting, and must not be breastfeeding. Men whose partners could become pregnant must agree to use highly effective contraception and avoid donating sperm during the same period.

Who may not be able to join:

  • People with a known or suspected allergy to any ingredient in the study medication, or those with a history of multiple or severe drug or food allergies, or a history of severe allergic reactions.
  • People with a history of, or currently experiencing, serious conditions affecting the heart, hormonal system (other than primary obesity), mental health, nervous system, digestive system, lungs, blood, immune system, or urinary and reproductive systems, where the study doctor considers participation unsuitable.
  • People who have had a serious injury or major surgery in the 6 months before screening, or who plan to have surgery during the study.
  • People who have taken part in another clinical trial or used an investigational drug or medical device within 3 months before screening (or within 5 half-lives of that investigational drug, whichever is longer), or who plan to do so during the study.
  • People who have made significant changes to their diet or exercise habits in the month before screening, or who are unlikely to maintain a stable diet and exercise routine during the study.
  • People with a known or suspected history of drug or substance misuse, or those who test positive on a urine drug screen during screening.
  • People who, in the study doctor's judgement, have any other circumstances that could interfere with the study results or make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-81220121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
8 May 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov